#direct-acting antivirals

However, people who are not successfully treated may continue to experience declines in mental health.

Pickings for concurrent treatment are slim in Ending the HIV Epidemic rural communities.

Pairing HCV testing and treatment eliminates the need to navigate the medical system.

The number of people treated with direct-acting antiviral therapy for hepatitis C has steadily declined.

The number of people treated for hepatitis C hit a low point during the COVID-19 pandemic.

People who received a shortened course of antiviral therapy were less likely to be cured.

Timely testing and treatment could improve outcomes for young people who inject drugs.

Cirrhosis severity and CD4 cell counts were linked to a greater chance of developing liver cancer.

Barriers still stand in the way of making treatment available to all who need it.

The Epclusa and Mavyret combination pills are now indicated for kids as young as age 3.

Despite limited testing and clinical visits, 95% of the study population was able to achieve a sustained virological response.

Rates of liver complications were similar, but HIV-positive people had more non-liver cancers and non-liver-related deaths.

Pharmacist-driven hep C treatment sees good cure rates

Researchers conducted an analysis of hep C treatment outcomes in those also living with HIV in Western nations.

Large European study finds that more than 1 in 10 people with HIV acquire HCV again.